Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: $XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect X4 Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of X4 Pharmaceuticals's position in the market.
X4 Pharmaceuticals reported financial results for the first quarter of 2024, with $81.6 million in cash. The FDA approved XOLREMDI for WHIM syndrome, and a Phase 3 trial data was published. Interim data from a Phase 2 trial in chronic neutropenia is expected in June 2024. X4 plans to initiate a Phase 3 trial for autoimmune and chronic neutropenia. The company expects EMA approval for mavorixafor in late 2024/early 2025.
Despite promising developments, X4 reported an increase in R&D and SG&A expenses, leading to a net loss of $51.8 million for the first quarter of 2024.
X4 Pharmaceuticals announced the issuance of inducement awards to new employees under the 2019 Inducement Plan, consisting of options to purchase 605,349 shares of X4's common stock. The options have a ten-year term, with an exercise price of $1.12 per share, and will vest over a four-year period, subject to continued employment.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will report first-quarter 2024 financial results on May 7, 2024, and host a conference call and webcast. The company focuses on rare immune system diseases, aiming to enhance patient lives.
X4 Pharmaceuticals (Nasdaq: XFOR)has announced the approval of XOLREMDI™ (mavorixafor) capsules by the FDA. The drugis the first of its kind, targeting patients with WHIM syndrome and is the first drug specifically indicated for the condition. The company has been granted a Rare Pediatric Disease Priority Review Voucher (PRV) concurrent with the approvaland the clinical trial resultshave been positive, with XOLREMDItreatment showingimprovementin ANC, ALC, and a reduction in infections for patients with WHIM syndrome. This milestone has been achieved after the successful completion of the 4WHIM Phase 3 clinical trial. The drug is expected to be commercially available for U.S. patients soon through X4's specialty pharmacy partner, PANTHERx® Rare. Along with the drug's approval, X4 has also announced the launch of X4ConnectTM, which will provide support to eligible U.S. patients, including resources and copay assistance.
